COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...
Saved in:
Main Authors: | E. G. Kosolapov (Author), F. S. Kochenkov (Author), N. L. Pogudina (Author), D. V. Blinov (Author), N. L. Bondarenko (Author), A. V. Karaulov (Author) |
---|---|
Format: | Book |
Published: |
IRBIS LLC,
2017-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017) -
New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol
by: Cazzola M, et al.
Published: (2013) -
Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD
by: Pelaia G, et al.
Published: (2015) -
Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation
by: S. V. Nedogoda, et al.
Published: (2020) -
COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA
by: N. L. Pogudina, et al.
Published: (2017)